RxDoctor Payments DataLook up a doctor →

Maria Carmen Wilson, MD

Neurology · Covington, LANPI 1093738148

Payments from drug & device makers

$681,133in general payments, 2019–2025

Across 720 payments — averaging $946.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$430K
  • Teva Pharmaceuticals USA, Inc.$79K
  • Lilly USA, LLC$68K
  • Amgen$56K
  • Biohaven Pharmaceuticals, Inc.$13K
  • Axsome Therapeutics, Inc.$10K
  • plus $26K from 16 others
$58in research payments, 2019–2025

Across 1 payment — averaging $57.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$58

What the payments were for

  • Consulting fees$26,7249%
  • Speaking & faculty fees$251,26485%
  • Grants$440%
  • Travel & lodging$8,6083%
  • Food & beverage$8,3903%
  • Education$2260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$681,133 in reported general payments places this provider in the 95th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$43,892
Medicare patients
112
Services billed
415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate191$290,706
Emgality PenGalcanezumab-Gnlm276$213,379
UbrelvyUbrogepant145$188,591
QuliptaAtogepant164$174,583
Aimovig AutoinjectorErenumab-Aooe95$68,270
Ajovy AutoinjectorFremanezumab-Vfrm24$18,896
LyricaPregabalin11$11,424
Topiramate ErTopiramate11$8,713
Eletriptan HbrEletriptan Hydrobromide47$8,136
Baclofen39$5,061
Sumatriptan Succinate160$3,497
Carbamazepine ErCarbamazepine15$2,459
Gabapentin184$2,350
RizatriptanRizatriptan Benzoate117$2,346
Fentanyl11$1,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$430,363$363,175309 claims
PfizerNurtec Odt, Lyrica$5,105$302,130202 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 neurology providers in Louisiana.

Other neurology in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →